Alcon: UBS raises its target slightly

(CercleFinance.com) - UBS reaffirms its 'buy' recommendation on Alcon, with a price target raised slightly from 92 to 93.
5 Swiss francs, a new target with 12% upside potential for the Swiss ophthalmology laboratory's stock.

Meetings with the CEO make us more optimistic for product launches in 2025, although short-term investments in overheads and administration will be necessary to support strong revenue growth", the broker believes.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.